

# Donal Brennan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5624781/publications.pdf>

Version: 2024-02-01

97  
papers

7,039  
citations

94269

37  
h-index

58464

82  
g-index

104  
all docs

104  
docs citations

104  
times ranked

12012  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mid-luteal uterine artery Doppler indices in the prediction of pregnancy outcome in nulliparous women undergoing assisted reproduction. <i>Human Fertility</i> , 2022, 25, 670-676.	0.7	2
2	Comparing three-dimensional models of placenta accreta spectrum with surgical findings. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 157, 188-197.	1.0	12
3	HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	3
4	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	33
5	Using menopausal hormone therapy after a cancer diagnosis in Ireland. <i>Irish Journal of Medical Science</i> , 2022, , 1.	0.8	2
6	Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report. <i>Case Reports in Women's Health</i> , 2022, 34, e00395.	0.2	0
7	Endocervical adenocarcinoma in situ with ovarian metastases. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 566-569.	1.2	0
8	Living beyond placenta accreta spectrum: parent's experience of the postnatal journey and recommendations for an integrated care pathway. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 397.	0.9	8
9	Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 352-359.	1.2	15
10	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , 2021, 10, 208-219.	1.3	69
11	Multidisciplinary Surgical Approach to Increase Complete Cytoreduction Rates for Advanced Ovarian Cancer in a Tertiary Gynecologic Oncology Center. <i>Annals of Surgical Oncology</i> , 2021, 28, 4553-4560.	0.7	11
12	Cytoreductive Surgery and HIPEC: An audit of early early post-operative surgical re-intervention. <i>European Journal of Surgical Oncology</i> , 2021, 47, e29-e30.	0.5	0
13	Quality of life and sexual function after a pregnancy complicated by placenta accreta spectrum. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, 708-714.	0.4	8
14	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 647-655.	1.2	28
15	Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints. <i>Trends in Cell Biology</i> , 2021, 31, 224-235.	3.6	16
16	Medical students' attitudes towards the teaching of cervical and ovarian cancer screening protocols in Ireland: a qualitative study. <i>Irish Journal of Medical Science</i> , 2021, , 1.	0.8	0
17	The impact of body composition on treatment in ovarian cancer: a current insight. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1065-1074.	1.3	11
18	Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination. <i>JAMA Network Open</i> , 2021, 4, e2115321.	2.8	11

#	ARTICLE	IF	CITATIONS
19	Time to Evolve Terminology from "Debulking" to Cytoreductive Surgery (CRS) in Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 5805-5807.	0.7	6
20	Authors' response to letter to the editor: Quality of life after placenta accreta spectrum: Should women be informed of mortality risk?. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2021, 61, E25.	0.4	0
21	The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100796.	0.3	7
22	From physical to virtual: How the COVID-19 pandemic changed a tertiary gynaecologic oncology surveillance program in Ireland. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100804.	0.3	1
23	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. <i>Clinical Epigenetics</i> , 2021, 13, 168.	1.8	14
24	Immunological assessment of SARS-CoV-2 infection in pregnancy from diagnosis to delivery: A multicentre prospective study. <i>PLoS ONE</i> , 2021, 16, e0253090.	1.1	3
25	Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2358-2362.	0.5	5
26	Maternal morbidity in placenta accreta spectrum following introduction of a multi-disciplinary service compared to standard care: an Irish perspective. <i>Irish Journal of Medical Science</i> , 2021, 190, 1451-1457.	0.8	10
27	Language and medicine: Breaking the barriers in gynaecological cancer. <i>Case Reports in Women's Health</i> , 2021, 32, e00361.	0.2	0
28	The menopause after cancer study (MACS) - A multimodal technology assisted intervention for the management of menopausal symptoms after cancer " Trial protocol of a phase II study. <i>Contemporary Clinical Trials Communications</i> , 2021, 24, 100865.	0.5	2
29	In Vitro User Assessment of a Novel Wound Protection and Specimen Extraction System for Laparoscopic Procedures Involving Morcellation. <i>Surgical Technology International</i> , 2021, 39, 34-37.	0.1	0
30	O-B04 The effect of high fat diet and subsequent intentional weight loss on tumour burden in an animal model of spontaneous endometrial cancer. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	0
31	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. <i>British Journal of Cancer</i> , 2020, 122, 361-371.	2.9	38
32	Quality of life following minimally invasive hysterectomy compared to abdominal hysterectomy: A meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 206-212.	0.5	10
33	The impact of accurately timed mid-luteal endometrial injury in nulligravid women undergoing their first or second embryo transfer. <i>Irish Journal of Medical Science</i> , 2020, 190, 1071-1077.	0.8	1
34	The Molecular Effects of a High Fat Diet on Endometrial Tumour Biology. <i>Life</i> , 2020, 10, 188.	1.1	4
35	A life changing experience: An interpretative phenomenological analysis of women's experiences of placenta accreta spectrum. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 254, 102-108.	0.5	9
36	Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 888-892.	1.2	59

#	ARTICLE	IF	CITATIONS
37	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	1.2	21
38	Patient perceptions and understanding of obesity related endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100545.	0.3	8
39	Mitogen-Activated Protein Kinase (MAPK) and Obesity-Related Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1241.	1.8	49
40	Evaluating liquid biopsies for methylomic profiling of prostate cancer. <i>Epigenetics</i> , 2020, 15, 715-727.	1.3	13
41	Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 777-782.	1.2	20
42	The Impact of Sarcopenia and Low Muscle Attenuation on Overall Survival in Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 3553-3564.	0.7	21
43	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 417-431.	0.6	48
44	Molecular basis of distinct oestrogen responses in endometrial and breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 31-46.	1.6	14
45	Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis. <i>Pleura and Peritoneum</i> , 2019, 4, 20190014.	0.5	12
46	A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. <i>Gynecologic Oncology</i> , 2019, 154, 622-630.	0.6	35
47	<scp>FIGO</scp> classification for the clinical diagnosis of placenta accreta spectrum disorders. <i>International Journal of Gynecology and Obstetrics</i> , 2019, 146, 20-24.	1.0	312
48	ER and PR expression and survival after endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 258-266.	0.6	49
49	Association of Implementing a Multidisciplinary Team Approach in the Management of Morbidly Adherent Placenta With Maternal Morbidity and Mortality. <i>Obstetrics and Gynecology</i> , 2018, 132, 1167-1176.	1.2	39
50	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 606-624.	8.2	69
51	Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. <i>Disease Markers</i> , 2018, 2018, 1-11.	0.6	131
52	G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7077-7082.	3.3	105
53	Response to "Surgical management of abnormally invasive placenta: is decreased blood loss due to participation of gynecologic oncologists?" <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 120-120.	1.3	0
54	Surgical safety and personal costs in morbidly obese, multimorbid patients diagnosed with early-stage endometrial cancer having a hysterectomy. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 1.	3.6	25

#	ARTICLE	IF	CITATIONS
55	Surgical Management of Abnormally Invasive Placenta: A Retrospective Cohort Study Demonstrating the Benefits of a Standardized Operative Approach. <i>Obstetric Anesthesia Digest</i> , 2016, 36, 203-204.	0.0	0
56	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 417-426.	2.9	35
57	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	0.8	29
58	Surgical management of abnormally invasive placenta: a retrospective cohort study demonstrating the benefits of a standardized operative approach. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 1380-1386.	1.3	38
59	Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. <i>BMC Cancer</i> , 2015, 15, 33.	1.1	41
60	Elevated amniotic fluid lactate predicts labor disorders and cesarean delivery in nulliparous women at term. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 673.e1-673.e8.	0.7	19
61	Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. <i>Human Pathology</i> , 2014, 45, 1509-1519.	1.1	16
62	Serum HE4 as a prognostic marker in endometrial cancer – A population based study. <i>Gynecologic Oncology</i> , 2014, 132, 159-165.	0.6	86
63	Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. <i>Cancer Research</i> , 2013, 73, 1128-1141.	0.4	797
64	Natural history, management, and outcomes of peripartum cardiomyopathy: an Irish single-center cohort study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 161-165.	0.7	12
65	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2012, 72, 66-75.	0.4	189
66	miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2012, 18, 6702-6713.	3.2	75
67	Maternal and fetal cocaine- and amphetamine-regulated transcript in diabetic and non-diabetic pregnancy. <i>Gynecological Endocrinology</i> , 2012, 28, 682-685.	0.7	3
68	RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. <i>Translational Oncology</i> , 2011, 4, 212-IN1.	1.7	54
69	Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. <i>Breast Cancer Research</i> , 2011, 13, R12.	2.2	22
70	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 937-948.	2.1	209
71	The Singleton, Cephalic, Nulliparous Woman After 36 Weeks of Gestation. <i>Obstetrics and Gynecology</i> , 2011, 117, 273-279.	1.2	67
72	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. <i>Modern Pathology</i> , 2011, 24, 708-719.	2.9	31

#	ARTICLE	IF	CITATIONS
73	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6083-6096.	3.2	330
74	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	7.7	1,486
75	The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. <i>Biochemical Society Transactions</i> , 2011, 39, 663-668.	1.6	32
76	Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. <i>BMC Cancer</i> , 2010, 10, 125.	1.1	39
77	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. <i>Nature Reviews Cancer</i> , 2010, 10, 605-617.	12.8	181
78	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. <i>Cancer Research</i> , 2010, 70, 7776-7787.	0.4	25
79	Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 78.	1.8	74
80	FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. <i>Carcinogenesis</i> , 2010, 31, 1417-1423.	1.3	110
81	Pulmonary Embolism in Pregnancy: Comparison of Pulmonary CT Angiography and Lung Scintigraphy. <i>American Journal of Roentgenology</i> , 2009, 193, 1223-1227.	1.0	119
82	Comparative analysis of international cesarean delivery rates using 10-group classification identifies significant variation in spontaneous labor. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 308.e1-308.e8.	0.7	174
83	299: Identification of a myometrial molecular profile for dystocic labor. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, S120-S121.	0.7	0
84	Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. <i>International Journal of Cancer</i> , 2009, 124, 2088-2097.	2.3	128
85	JAM-3 expression positively correlates with poor prognosis in breast cancer patients. <i>International Journal of Cancer</i> , 2009, 125, 1343-1351.	2.3	115
86	Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. <i>Modern Pathology</i> , 2009, 22, 1564-1574.	2.9	69
87	The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2009, 45, 1510-1517.	1.3	79
88	Prognostic Significance of Stromal Platelet-Derived Growth Factor $\beta$ 2-Receptor Expression in Human Breast Cancer. <i>American Journal of Pathology</i> , 2009, 175, 334-341.	1.9	215
89	Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R79.	2.2	52
90	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R89.	2.2	113

#	ARTICLE	IF	CITATIONS
91	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2681-2689.	3.2	83
92	Breast cancer proteomics: clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 209-219.	1.4	8
93	Survivin: A promising tumor biomarker. <i>Cancer Letters</i> , 2007, 249, 49-60.	3.2	229
94	CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. <i>International Journal of Cancer</i> , 2007, 120, 1434-1443.	2.3	98
95	Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. <i>Cancer Genomics and Proteomics</i> , 2007, 4, 121-34.	1.0	17
96	CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. <i>Clinical Cancer Research</i> , 2006, 12, 6421-6431.	3.2	123
97	Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1069-1083.	1.4	46